Unusual 11 Mid-Day Movers 06/07: (TIN) (ENMD) (EXEL) Higher; (TLB) (PBY) (NEOP) Lower
Tweet
Share
E-mail
Get Alerts TIN Hot Sheet
Join SI Premium – FREE
Temple-Inland (NYSE: TIN) 39.8% HIGHER; International Paper today announced that it has proposed to acquire all of the outstanding shares of Temple-Inland for $30.60 per share in cash.
Talbots, Inc. (NYSE: TLB) 38.7% LOWER; reported Q1 EPS of $0.08, 5 cents better than the analyst estimate of $0.03. Revenue for the quarter came in at $301.3 million versus the consensus estimate of $306.26 million. Same-store sales fell 6.5%. Sees Q2 sales, gross margin lower compared to last year.
EntreMed, Inc. (Nasdaq: ENMD) 19.7% HIGHER; announced that Selected Value Therapeutics I, LLC has exercised its right to acquire an exclusive license to develop and commercialize EntreMed's Phase 2 oncology drug candidate, ENMD-2076, in China and certain of its territories. EntreMed retains development and commercialization rights to ENMD-2076 in the rest of the world.
Pep Boys-Manny Moe & Jack (NYSE: PBY) 18.3% LOWER; reported Q1 EPS of $0.23, 7 cents worse than the analyst estimate of $0.30. Revenue for the quarter came in at $513.5 million versus the consensus estimate of $537.03 million. Same-store sales fell 0.6 percent.
NeoProbe (Nasdaq: NEOP) 15.1% LOWER; continuing lower today amid full Phase 3 lymphoseek study results at ASCO yesterday. The stock fell more than 10 percent.
Exelixis, Inc. (Nasdaq: EXEL) 14.7% HIGHER; bouncing today following a slight sell off yesterday on cabozantinib phase 2 data from ASCO.
51job (Nasdaq: JOBS) 14.3% LOWER; traders may be selling the stock today following data from the Bureau of Labor Statistics on job openings. The agency said job openings fell to 2,972 on the last day in April.
FriendFinder Networks (Nasdaq: FFN) 13% HIGHER; reported Q1 loss of $0.27 per share, versus ($0.60) reported last year. Revenue for the quarter came in at $83.5 million.
G-III Apparel Group Ltd (Nasdaq: GIII) 12.7% LOWER; reported Q1 loss of $0.03, 7 cents worse than the analyst estimate of $0.04. Revenue for the quarter came in at $196.9 million versus the consensus estimate of $195.36 million. Sales for Q2 are expected to be $215 million while EPS is forecast to be around 18 to 22 cents. The consensus call for sales of $221.24 million and earnings of 22 cents per share.
Pharmacyclics, Inc. (Nasdaq: PCYC) 11.1% HIGHER; yesterday afternoon announced data from the oral presentation of the Phase IB/II study of the Btk inhibitor, PCI-32765, in chronic lymphocytic leukemia / small cell lymphocytic lymphoma at the 2011 American Society of Clinical Oncology Annual Meeting. Click here to see full results from the study.
Inhibitex (Nasdaq: INHX) 10.4% HIGHER; traders seem to be buying the dip today following four straight sessions of downside. Over this span, the stock fell 14.5 percent.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Talbots, Inc. (NYSE: TLB) 38.7% LOWER; reported Q1 EPS of $0.08, 5 cents better than the analyst estimate of $0.03. Revenue for the quarter came in at $301.3 million versus the consensus estimate of $306.26 million. Same-store sales fell 6.5%. Sees Q2 sales, gross margin lower compared to last year.
EntreMed, Inc. (Nasdaq: ENMD) 19.7% HIGHER; announced that Selected Value Therapeutics I, LLC has exercised its right to acquire an exclusive license to develop and commercialize EntreMed's Phase 2 oncology drug candidate, ENMD-2076, in China and certain of its territories. EntreMed retains development and commercialization rights to ENMD-2076 in the rest of the world.
Pep Boys-Manny Moe & Jack (NYSE: PBY) 18.3% LOWER; reported Q1 EPS of $0.23, 7 cents worse than the analyst estimate of $0.30. Revenue for the quarter came in at $513.5 million versus the consensus estimate of $537.03 million. Same-store sales fell 0.6 percent.
NeoProbe (Nasdaq: NEOP) 15.1% LOWER; continuing lower today amid full Phase 3 lymphoseek study results at ASCO yesterday. The stock fell more than 10 percent.
Exelixis, Inc. (Nasdaq: EXEL) 14.7% HIGHER; bouncing today following a slight sell off yesterday on cabozantinib phase 2 data from ASCO.
51job (Nasdaq: JOBS) 14.3% LOWER; traders may be selling the stock today following data from the Bureau of Labor Statistics on job openings. The agency said job openings fell to 2,972 on the last day in April.
FriendFinder Networks (Nasdaq: FFN) 13% HIGHER; reported Q1 loss of $0.27 per share, versus ($0.60) reported last year. Revenue for the quarter came in at $83.5 million.
G-III Apparel Group Ltd (Nasdaq: GIII) 12.7% LOWER; reported Q1 loss of $0.03, 7 cents worse than the analyst estimate of $0.04. Revenue for the quarter came in at $196.9 million versus the consensus estimate of $195.36 million. Sales for Q2 are expected to be $215 million while EPS is forecast to be around 18 to 22 cents. The consensus call for sales of $221.24 million and earnings of 22 cents per share.
Pharmacyclics, Inc. (Nasdaq: PCYC) 11.1% HIGHER; yesterday afternoon announced data from the oral presentation of the Phase IB/II study of the Btk inhibitor, PCI-32765, in chronic lymphocytic leukemia / small cell lymphocytic lymphoma at the 2011 American Society of Clinical Oncology Annual Meeting. Click here to see full results from the study.
Inhibitex (Nasdaq: INHX) 10.4% HIGHER; traders seem to be buying the dip today following four straight sessions of downside. Over this span, the stock fell 14.5 percent.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- Symrise AG (SY1:GR) (SYIEY) PT Raised to EUR120 at CFRA
- Ladder Capital (LADR) Tops Q1 EPS by 4c
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Unusual 11 Mid-Day Movers, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
